The Patent Finder

Combination Therapy for Cancer Treatment

Ipsen Biopharm Ltd.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 3 of these applications claim priority to application PCT/US2016/047827, filed Aug 19, 2016. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 9,895,365Combination Therapy for Cancer Treatment
In force
 · High confidence
Ipsen Biopharm Ltd.In force
High confidence
US 10,478,428Combination Therapy for Cancer Treatment
In force
 · Medium confidence
Ipsen Biopharm Ltd.In force
Medium confidence
US 11,844,795Combination Therapy for Cancer Treatment
In force
 · Medium confidence
Ipsen Biopharm Ltd.In force
Medium confidence
Application 16/586,609Combination Therapy for Cancer Treatment
Abandoned
Abandoned Apr 11, 2022
Ipsen Biopharm Ltd.AbandonedAbandoned Apr 11, 2022
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Ipsen Biopharm Ltd..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited